Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Trial Profile

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Nutritional and metabolic diseases; Obesity
  • Focus Therapeutic Use
  • Acronyms SCALE™ IBT
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 05 May 2017 Planned End Date changed from 22 Jun 2018 to 21 Jun 2018.
    • 05 May 2017 Planned primary completion date changed from 23 May 2018 to 22 May 2018.
    • 05 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top